Inactive Instrument

Apexigen, Inc.

Equities

APGN

US03759B1026

Biotechnology & Medical Research

Apexigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 16, 2023 at 02:08 am IST

Apexigen, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 6.05 million compared to USD 9.04 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.5 a year ago.

Latest news about Apexigen, Inc.

Apexigen, Inc.(NasdaqCM:APGN) dropped from S&P TMI Index	25/23/25	CI
Pyxis Oncology Completes Acquisition of Apexigen	23/23/23	MT
Apexigen, Inc.(NasdaqCM:APGN) dropped from NASDAQ Composite Index	23/23/23	CI
Pyxis Oncology, Inc. completed the acquisition of Apexigen, Inc. from entities associated with Pfizer Inc., Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.	23/23/23	CI
Apexigen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Apexigen, Inc. Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology 2023 Annual Meeting	03/23/03	CI
North American Morning Briefing : Nvidia Surge -2-	25/23/25	DJ
Wall Street Set to Open Lower as Investors Await Progress on Debt-Ceiling Talks Ahead of Fed Minutes Release	24/23/24	MT
Sector Update: Health Care Stocks Mixed Premarket Wednesday	24/23/24	MT
Sector Update: Health Care	24/23/24	MT
Transcript : Apexigen, Inc., Pyxis Oncology, Inc. - M&A Call	24/23/24
US Futures Lower as Investors Eye Debt Ceiling Talks, Await Fed Minutes Release	24/23/24	MT
Top Premarket Gainers	24/23/24	MT
Pyxis Oncology to Acquire Apexigen in $16 Million All-Stock Deal	24/23/24	MT
EF Hutton Adjusts Price Target on Apexigen to $5 From $8, Maintains Buy Rating	16/23/16	MT
Apexigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Apexigen Announces Review of Strategic Alternatives	27/23/27	CI
Apexigen Plans to Reduce its Workforce by 55%	27/23/27	CI
Apexigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23	CI
Apexigen, Inc. Auditor Raises 'Going Concern' Doubt	22/23/22	CI
Apexigen, Inc. Announces Executive Changes	14/23/14	CI
Apexigen, Inc. announced that it has received $5.587982 million in funding	14/23/14	CI
Apexigen, Inc. announced a financing transaction	30/23/30	CI
Apexigen, Inc. announced that it has received $2.793991 million in funding	30/23/30	CI
Roth Capital Reinstates Apexigen at Buy Rating With $15 Price Target	24/23/24	MT

Chart Apexigen, Inc.

Duration

Period

More charts

Company Profile

Apexigen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient's immune system to combat and eradicate cancer. It has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. It also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. It is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company's licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs